Bridging the Global TB Diagnostic Gap: The Clinical Rigor Behind EMPE TBDx
Bridging the Global TB Diagnostic Gap: The Clinical Rigor Behind EMPE TBDx Scalable, Platform-Agnostic, and…
Advancing Healthcare Diagnostics: Why Rwanda is the New Frontier for TB Innovation
Rwanda is rapidly positioning itself as one of the most attractive destinations for healthcare investment…
From Innovation to Access: Bridging the Last-Mile Gap in TB Diagnostics
We are not short of TB diagnostics. We are short of access. Each year, an…
Rapid Detection of M. tuberculosis and Its Resistance to Rifampicin and Isoniazid with the mfloDx™ MDR‑TB test
Background: Rapid detection of tuberculosis (TB) and its resistance are essential for the prompt initiation…
Tuberculosis Diagnostics Pipeline Report 2025
Tuberculosis (TB) is the leading cause of death from an infectious disease worldwide, claiming an…
Novel diagnostic test for the detection of Mycobacterium tuberculosis and its resistance to rifampicin, isoniazid, and fluoroquinolones directly in sputum samples
Introduction: Rapid identification of tuberculosis (TB) and its drug resistance is crucial for starting effective…
WHO Global TB Report 2023
New diagnosticsThe diagnostic pipeline has expanded considerably in terms of the number of tests, products…